Relmada TherapeuticsRLMD -1.57%29 Net Current Asset Value is $2.09 as of Mar. 2026, which is 53% below its 10-year median of 4.49. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, Relmada Therapeutics ranks better than 67.55% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Relmada Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was $2.09.
The historical rank and industry rank for Relmada Therapeutics's Net Current Asset Value or its related term are showing as below:
RLMD'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.4 Med: 4.49 Max: 236
Current: 3
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Relmada Therapeutics was 236.00. The lowest was 0.40. And the median was 4.49.
RLMD's Price-to-Net-Current-Asset-Value is ranked better than 67.55% of 943
companies
in the Biotechnology industry
Industry Median: 4.96
vs RLMD: 3.00
Relmada Therapeutics (NAS:RLMD) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Relmada Therapeutics Net Current Asset Value Related Terms
Relmada Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Relmada Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relmada Therapeutics Net Current Asset Value Chart
RLMD vs ACRS, GYRE, SGP: Net Current Asset Value Comparison
For the Biotechnology subindustry, Relmada Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relmada Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $2.09 mean?
Relmada Therapeutics (RLMD) has a Net Current Asset Value of $2.09 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Relmada Therapeutics and its competitors. This is 53% below median its historical median of 4.49. Over the past decade, Relmada Therapeutics' Net Current Asset Value has ranged from 0.40 to 236.00. According to the industry distribution chart, Relmada Therapeutics ranks #306 out of 943 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Relmada Therapeutics' Net Current Asset Value too high?
Relmada Therapeutics' current Net Current Asset Value of $2.09 is 53% below median its 10-year median of 4.49. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 236.00. The Biotechnology industry median Net Current Asset Value is 4.96. Relmada Therapeutics' value of $2.09 is 57.9% below this industry median. Based on the distribution chart, Relmada Therapeutics ranks #306 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' Net Current Asset Value compare to ACRS and GYRE?
According to the Biotechnology industry distribution chart, Relmada Therapeutics ranks #306 out of 943 companies for Net Current Asset Value. This puts Relmada Therapeutics in the upper half of its industry. The industry median Net Current Asset Value is 4.96. Relmada Therapeutics' value of $2.09 is 57.9% below this benchmark. Historically, Relmada Therapeutics' own Net Current Asset Value has ranged from 0.40 to 236.00 over the past decade. While the company's 10-year median is 4.49 vs. the industry median of 4.96, Relmada Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relmada Therapeutics's current Net Current Asset Value of $2.09 is 57.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Relmada Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relmada Therapeutics's current Net Current Asset Value is $2.09, which is 53% below median its own 10-year median of 4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current Net Current Asset Value of $2.09. The current Net Current Asset Value is $2.09, which is 53% below median its 10-year median of 4.49 and 57.9% below the Biotechnology industry median of 4.96. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current Net Current Asset Value is $2.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score
Get the complete analysis for RLMD
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLMD has been successfully added to your 
